ACET - Adicet Bio, Inc.

8.31
0.250   3.008%

Share volume: 58,334
Last Updated: 04-22-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.18%

PREVIOUS CLOSE
CHG
CHG%
$8.06
0.25
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
43%
Profitability 40%
Dept financing 22%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.15%
1 Month
24.77%
3 Months
-1.54%
6 Months
864.93%
1 Year
1,281.78%
2 Year
295.71%
Key data
Stock price
$8.31
P/E Ratio 
N/A
DAY RANGE
$8.14 - $8.42
EPS 
-$5.37
52 WEEK RANGE
$0.46 - $9.05
52 WEEK CHANGE
$1,252.98
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
9.596 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
1.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$202,471
AVERAGE 30 VOLUME 
$147,757
Company detail
CEO: Chen Schor
Region: US
Website: adicetbio.com
Employees: 90
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Adicet Bio, Inc. discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. Lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma.

Recent news